The Security Committee of the European Medicine Agency has concluded that the use of Novo Nordisk’s popular weight-loss drug wagovi and its treatment for type 2 diabetes can lead to rare events of potentially dangerous eye conditions.

The regulator stated that the non-artificic anterior ischemic optic neuropathy (Naion) is called, the condition may be affected to 1 in 10,000 people taking semaglutide, active ingredients in the vegovi and the diabetes drugs ozmpic and ribellas, the diabetes drug ozmpic and ribellas, said on Friday.

The EMA, which began its review in December, stated that drugs are almost twice the risk of developing the situation compared to the people who do not take the drugs.

Neither develops from insufficient blood flow to the optic nerve and causes a sudden painless vision loss in an eye. This is the second most common cause of blindness due to optic nerve damage after glaucoma.

Studies have connected semaglutide to Naion in the past. But this is the first time a regulator has created a link.

Semaglutide GLP-1 belongs to a section of drugs known as a receptor agonist, which works by helping to control blood sugar levels and trigger a sense of perfection.

A major study of about 350,000 diabetic patients published earlier this year showed that the risk of developing more than doubling after long -term use of semaglutide, compared to patients taking drugs from other sections.

The EMA said that it reviewed all available data on NAION, including non-ninth studies, clinical testing and post-marketing data

Supervision.

It recommends the drug manufacturer to determine information for drugs containing semaglutide to include NAION as a side effect with the frequency of “very rare”.

The US Food and Drug Administration did not immediately respond to Reuters’ request for comments.